Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia.

Literature DB >> 1508406

Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia.

H Tohgi¹, T Abe, S Takahashi, M Kimura, J Takahashi, T Kikuchi.

Abstract

We studied concentrations of free and total serotonin (5-hydroxytryptamine, 5-HT) and its related substances in the cerebrospinal fluid from patients with Alzheimer type dementia (ATD) compared with controls. In ATD patients, concentrations of total 5-HT, tryptophan, 5-hydroxytryptophan (5-HTP), melatonin, kynurenine, and 3-hydroxykynurenine decreased significantly. The rate of concentration of tryptophan metabolites to that of tryptophan was significantly reduced for total 5-HT and 3-hydroxykynurenine only. The 5-hydroxyindoleacetic acid (5-HIAA)/5-HT ratio was significantly larger in ATD patients than in controls. The greater reduction in the 3-hydroxykynurenine concentration (81% vs. controls) than in the total 5-HT concentration (51% vs. controls) suggests that the metabolism of tryptophan to 5-HT and 3-hydroxykynurenine is in favor of 5-HT.

Entities: Chemical Disease Species

Mesh：

Substances：
Amino Acids
Serotonin

Year: 1992 PMID： 1508406 DOI： 10.1016/0304-3940(92)90322-x

Source DB: PubMed Journal: Neurosci Lett ISSN： 0304-3940 Impact factor: 3.046

Keyword Cloud
Cited

15 in total

1. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia.

Authors: H Tohgi; T Abe; M Kimura; M Saheki; S Takahashi
Journal: J Neural Transm (Vienna) Date: 1996 Impact factor: 3.575

Review 9. The Role of Sleep and Sleep Disorders in the Development, Diagnosis, and Management of Neurocognitive Disorders.

Authors: Michelle A Miller
Journal: Front Neurol Date: 2015-10-23 Impact factor: 4.003

10. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.

Authors: Alan G Wade; Mildred Farmer; Gil Harari; Naama Fund; Moshe Laudon; Tali Nir; Anat Frydman-Marom; Nava Zisapel
Journal: Clin Interv Aging Date: 2014-06-18 Impact factor: 4.458

Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia.

1. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia.

Review 2. Therapy for Insomnia and Circadian Rhythm Disorder in Alzheimer Disease.

Review 3. Circadian rhythm sleep disorders: pathophysiology and potential approaches to management.

Review 4. From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic Opportunities for 5-HT3 Receptor Antagonists.

5. Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease.

Review 6. The serotonergic system and cognitive function.

Review 7. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation.

Review 8. Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology.

Review 9. The Role of Sleep and Sleep Disorders in the Development, Diagnosis, and Management of Neurocognitive Disorders.

10. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.